Vitamin D and miRNAs in cancer

Current Gene Therapy

Volumn 14, Issue 4, 2014, Pages 269-275

  Ma, Yingyu ^a   Trump, Donald L ^a   Johnson, Candace S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Calcitriol; Cancer; microRNA; Vitamin D

Indexed keywords

1, 25 DIHYDROXYERGOCALCIFEROL; MICRORNA; MICRORNA 100; MICRORNA 106B; MICRORNA 125B; MICRORNA 130A; MICRORNA 134; MICRORNA 135B; MICRORNA 146A; MICRORNA 181A; MICRORNA 181B; MICRORNA 181D; MICRORNA 182; MICRORNA 21; MICRORNA 22; MICRORNA 27B; MICRORNA 29A; MICRORNA 29B; MICRORNA 302C; MICRORNA 32; MICRORNA 498; MICRORNA 520C; MICRORNA 627; MICRORNA 98; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; COLON CANCER; GENE EXPRESSION; HUMAN; LEUKEMIA; LUNG CANCER; MELANOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROSTATE CANCER; SIGNAL TRANSDUCTION; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NEOPLASMS; OVARIAN NEOPLASMS; PHYSIOLOGY; PROSTATIC NEOPLASMS; VITAMIN D RESPONSIVE ELEMENT;

COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; MALE; MICRORNAS; NEOPLASMS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; VITAMIN D; VITAMIN D RESPONSE ELEMENT;

EID: 84907152031     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666140612153537     Document Type: Article

References (69)

1. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277: F157-75.
2. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7: 684-700.
3. Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 2004; 3: 27-41.
4. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252-61.
5. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98: 451-9.
6. McElwain MC, Modzelewski RA, Yu WD, Russell DM, Johnson CS. Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol 1997; 18: 293-8.
7. Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997; 50: 999-1006.
8. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1, 25-Dihydroxycholecalciferol (1, 25-D3) inhibits the growth of squamous cell carcinoma and downmodulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 1999; 59: 2644-9.
9. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001; 7: 1043-51.
10. VanWeelden K, Flanagan L, Binderup L, Tenniswood M, Welsh J. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 1998; 139: 2102-10.
11. Zhang X, Jiang F, Li P, et al. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res 2005; 11: 323-8.
12. Konety BR, Lavelle JP, Pirtskalaishvili G, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 2001; 165: 253-8.
13. Grau MV, Baron JA, Sandler RS, et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003; 95: 1765-71.
14. Wu G, Fan RS, Li W, Ko TC, Brattain MG. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene 1997; 15: 1555-63.
15. Hershberger PA, McGuire TF, Yu WD, et al. Cisplatin potentiates 1, 25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 2002; 1: 821-9.
16. Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 2001; 276: 9101-7.
17. Guzey M, Kitada S, Reed JC. Apoptosis induction by 1alpha, 25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002; 1: 667-77.
18. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 2000; 60: 2304-12.
19. Ma Y, Yu WD, Kong RX, Trump DL, Johnson CS. Role of Nongenomic Activation of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathways in 1, 25D3-Mediated Apoptosis in Squamous Cell Carcinoma Cells. Cancer Res 2006; 66: 8131-8.
20. Perkins SL, Link DC, Kling S, Ley TJ, Teitelbaum SL. 1, 25-Dihydroxyvitamin D3 induces monocytic differentiation of the PLB-985 leukemic line and promotes c-fgr mRNA expression. J Leukoc Biol 1991; 50: 427-33.
21. Oliveira NL, Kalf GF. Induced differentiation of HL-60 promyelocytic leukemia cells to monocyte/macrophages is inhibited by hydroquinone, a hematotoxic metabolite of benzene. Blood 1992; 79: 627-33.
22. Bonewald LF, Kester MB, Schwartz Z, et al. Effects of combining transforming growth factor beta and 1, 25-dihydroxyvitamin D3 on differentiation of a human osteosarcoma (MG-63). J Biol Chem 1992; 267: 8943-9.
23. Cho YL, Christensen C, Saunders DE, et al. Combined effects of 1, 25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 1991; 51: 2848-53.
24. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997; 57: 3759-64.
25. Ting HJ, Hsu J, Bao BY, Lee YF. Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha, 25-dihydroxyvitamin D3. Cancer Lett 2007; 247: 122-9.
26. Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. J Cancer 2010; 1: 101-7.
27. Moazed D. Small RNAs in transcriptional gene silencing and genome defence. Nature 2009; 457: 413-20.
28. Malone CD, Hannon GJ. Small RNAs as guardians of the genome. Cell 2009; 136: 656-68.
29. Sharma V, Misteli T. Non-coding RNAs in DNA damage and repair. FEBS Lett 2013; 587: 1832-9.
30. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov 2011; 1: 391-407.
31. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-69.
32. Sontheimer EJ. Assembly and function of RNA silencing complexes. Nat Rev Mol Cell Biol 2005; 6: 127-38.
33. Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell 2013; 153: 516-9.
34. Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 2014; 124: 2136-46.
35. Yang X, Du WW, Li H, et al. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res 2013; 41: 9688-704.
36. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science 2008; 320: 97-100.
37. Liu N, Abe M, Sabin LR, et al. The exoribonuclease Nibbler controls 3' end processing of microRNAs in Drosophila. Curr Biol 2011; 21: 1888-93.
38. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 2010; 1803: 1231-43.
39. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009; 60: 167-79.
40. White NM, Fatoohi E, Metias M, Jung K, Stephan C, Yousef GM. Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol 2011; 8: 75-84.
41. Ting HJ, Messing J, Yasmin-Karim S, Lee YF. Identification of microRNA-98 as a Therapeutic Target Inhibiting Prostate Cancer Growth and a Biomarker Induced by Vitamin D. J Biol Chem 2013; 288: 1-9.
42. Giangreco AA, Vaishnav A, Wagner D, et al. Tumor suppressor microRNAs, miR-100 and-125b, are regulated by 1, 25-dihydroxyvitamin D in primary prostate cells and in patient tissue. Cancer Prev Res (Phila) 2013; 6: 483-94.
43. Wang WL, Chatterjee N, Chittur SV, Welsh J, Tenniswood MP. Effects of 1alpha, 25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer 2011; 10: 58.
44. Thorne JL, Maguire O, Doig CL, et al. Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res 2011; 39: 2045-56.
45. Poliseno L, Salmena L, Riccardi L, et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTENtargeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 2010; 3: ra29.
46. Wu WK, Law PT, Lee CW, et al. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 2011; 32: 247-53.
47. Alvarez-Diaz S, Valle N, Ferrer-Mayorga G, et al. MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum Mol Genet 2012; 21: 2157-65.
48. Guo MM, Hu LH, Wang YQ, et al. miR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1. Med Oncol 2013; 30: 542.
49. Shi C, Xu X. MicroRNA-22 is down-regulated in hepatitis B virus-related hepatocellular carcinoma. Biomed Pharmacother 2013; 67: 375-80.
50. Xu D, Takeshita F, Hino Y, et al. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol 2011; 193: 409-24.
51. Padi SK, Zhang Q, Rustum YM, Morrison C, Guo B. MicroRNA-627 Mediates the Epigenetic Mechanisms of Vitamin D to Suppress Proliferation of Human Colorectal Cancer Cells and Growth of Xenograft Tumors in Mice. Gastroenterology 2013; 145: 437-46.
52. Kasiappan R, Shen Z, Tse AK, et al. 1, 25-Dihydroxyvitamin D3 Suppresses Telomerase Expression and Human Cancer Growth through MicroRNA-498. J Biol Chem 2012; 287: 41297-309.
53. Guan H, Liu C, Chen Z, et al. 1, 25-Dihydroxyvitamin D3 upregulates expression of hsa-let-7a-2 through the interaction of VDR/VDRE in human lung cancer A549 cells. Gene 2013; 522: 142-6.
54. Essa S, Denzer N, Mahlknecht U, Klein R, Collnot EM, Tilgen W, Reichrath J. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J Steroid Biochem Mol Biol 2010; 121: 110-3.
55. Essa S, Reichrath S, Mahlknecht U, Montenarh M, Vogt T, Reichrath J. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines. Anticancer Res 2012; 32: 383-9.
56. Sonkoly E, Wei T, Pavez LE, et al. Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes. J Invest Dermatol 2010; 130: 124-34.
57. Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008; 135: 255-60.
58. Peng X, Vaishnav A, Murillo G, Alimirah F, Torres KE, Mehta RG. Protection against cellular stress by 25-hydroxyvitamin D3 in breast epithelial cells. J Cell Biochem 2010; 110: 1324-33.
59. Gocek E, Wang X, Liu X, Liu CG, Studzinski GP. MicroRNA-32 upregulation by 1, 25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraCinduced apoptosis. Cancer Res 2011; 71: 6230-9.
60. Wang X, Gocek E, Liu CG, Studzinski GP. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1, 25-dihydroxyvitamin D3. Cell Cycle 2009; 8: 736-41.
61. Zimmerman EI, Dollins CM, Crawford M, et al. Lyn kinasedependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol Pharmacol 2010; 78: 811-7.
62. Lutherborrow M, Bryant A, Jayaswal V, et al. Expression profiling of cytogenetically normal acute myeloid leukemia identifies microRNAs that target genes involved in monocytic differentiation. Am J Hematol 2011; 86: 2-11.
63. Min D, Lv XB, Wang X, et al. Downregulation of miR-302c and miR-520c by 1, 25(OH)2D3 treatment enhances the susceptibility of tumour cells to natural killer cell-mediated cytotoxicity. Br J Cancer 2013; 109: 723-30.
64. Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T. MicroRNA regulates human vitamin D receptor. Int J Cancer 2009; 125: 1328-33.
65. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009; 37: 2112-7.
66. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is posttranscriptionally regulated by miR-125b. Mol Pharmacol 2009; 76: 702-9.
67. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 2013; 329: 125-36.
68. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014; 11: 145-56.
69. Jorde R, Svartberg J, Joakimsen RM, Coucheron DH. Plasma profile of microRNA after supplementation with high doses of vitamin D3 for 12 months. BMC Res Notes 2012; 5: 245.